Higher Fracture Risk Not Seen With SGLT2 Inhibitors Higher Fracture Risk Not Seen With SGLT2 Inhibitors

Increased fracture risk seen in short-term studies may have been due to hypovolemia or osmotic diuresis, resulting in falls, rather than an effect on bone.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Source Type: news